<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927130</url>
  </required_header>
  <id_info>
    <org_study_id>AB PoC 2021 RUS</org_study_id>
    <nct_id>NCT04927130</nct_id>
  </id_info>
  <brief_title>Retrospective Comparative in Vitro Case-controlled Study of the Liquid Biopsy Test System in Women With Breast Cancer</brief_title>
  <official_title>An International Multicenter Blind Retrospective Comparative in Vitro Case-controlled Study of the ARNA Breast Liquid Biopsy Test System in Women With Biopsy Confirmed Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARNA Genomics US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BIOMARKER-RU</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ARNA Genomics US Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of Concept retrospective study. Women who have the diagnosis Breast Cancer ( confirmed&#xD;
      by biopsy) will donate a blood samples. Tubes with blood will be transferred to the Sponsors&#xD;
      Laboratory and ARNA Breast Test will be performed. The result of test will be compared with&#xD;
      the biopsy result for each person.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of true positive cases</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>the absolute total number of matches between the results of the test system and histological confirmation of the diagnosis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Neoplasm Female</condition>
  <arm_group>
    <arm_group_label>Women in age 35 to 65 with confirmed breast cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ARNA Breast</intervention_name>
    <description>A specific DNA fragments and globulins will be detected in blood plasma.</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Women in age 35 to 65 with confirmed breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women of the required age group, in case of breast cancer has been confirmed but not&#xD;
        treated, are sent to donate blood samples.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Availability of signed and dated informed consent.&#xD;
&#xD;
          -  Women from 35 to 65 years old, who are generally healthy, with confirmed breast&#xD;
             cancer. Or without any neoplasms in breast (control group)&#xD;
&#xD;
          -  Presence of a documented biopsy&#xD;
&#xD;
          -  Presence of mammography, ultrasound or MRI of the mammary glands no later than three&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Any other cancers diagnosed now or previously, with the exception of breast cancer.&#xD;
&#xD;
          -  Therapy with cytostatic during the last three months.&#xD;
&#xD;
          -  Chemotherapy within the past three months.&#xD;
&#xD;
          -  Therapy with hormonal drugs, including all forms of contraceptive drugs.&#xD;
&#xD;
          -  Therapy with other prohibited groups of drugs.&#xD;
&#xD;
          -  Systolic blood pressure &gt; 180 mm Hg. and / or diastolic blood pressure &gt; 120 mm Hg.&#xD;
             with repeated measurements.&#xD;
&#xD;
          -  Simultaneous participation in another clinical study.&#xD;
&#xD;
          -  Relative affiliation to the clinic, for example, the patient is a close relative of&#xD;
             the researcher or a dependent person (for example, a clinic employee or student or a&#xD;
             sponsor employee).&#xD;
&#xD;
          -  A clinically significant condition or laboratory result that, in the opinion of the&#xD;
             investigator, threatens the safety of the test subject, may interfere with&#xD;
             assessments, or prevent the completion of the study.&#xD;
&#xD;
          -  Failure to cooperate to participate in planned procedures, including the following&#xD;
             examples: lack of understanding of language, mental illness, inability to visit the&#xD;
             clinic.&#xD;
&#xD;
          -  Diseases or conditions that may affect the conduct of the study or the interpretation&#xD;
             of the results.&#xD;
&#xD;
          -  History of organ transplantation.&#xD;
&#xD;
          -  Blood transfusions within the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrey Tarabarov, MD</last_name>
    <phone>+79161048621</phone>
    <email>at@arna.bio</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Egor Melnikov</last_name>
    <phone>+79255022196</phone>
    <email>em@arna.bio</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>K+31</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Puchkova, MD</last_name>
      <phone>+79032730217</phone>
      <email>o.puchkova@k31.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

